Core Points - The article outlines the work rules of the Audit Committee of Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd, emphasizing the importance of internal control and financial oversight [1][2][3] Group 1: General Provisions - The Audit Committee is established to enhance corporate governance and ensure effective supervision of financial activities [1] - The committee operates independently and reports directly to the Board of Directors [1][2] Group 2: Composition of the Committee - The committee consists of at least three directors who are not senior management, with a majority being independent directors, including at least one accounting professional [2] - The term of committee members aligns with that of the Board, with independent directors limited to a maximum of six consecutive years [2][3] Group 3: Responsibilities and Authority - The main responsibilities include supervising external audit work, evaluating internal audit processes, and reviewing financial information [3][4] - The committee must approve significant financial disclosures and the hiring or dismissal of external auditors before submission to the Board [3][4] Group 4: Internal Audit Oversight - The committee supervises the internal audit department, ensuring it operates effectively and reports directly to the committee [9][10] - Internal audit findings must be reported to the committee, which also evaluates the effectiveness of internal controls [10][11] Group 5: Meeting Procedures - The committee holds regular meetings at least quarterly, with special meetings convened as necessary [28][29] - Decisions require a majority vote from attending members, and detailed records of meetings must be maintained [30][31] Group 6: Reporting and Evaluation - The committee is required to submit annual reports on its activities and evaluations of external auditors to the Board [15][16] - It also has the authority to propose the convening of extraordinary shareholder meetings when necessary [6][7]

General Provisions - The rules are established to regulate the behavior of Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd. and ensure shareholders can exercise their rights according to relevant laws and regulations [1][2] - The company must strictly follow legal and regulatory requirements when convening shareholder meetings [1][3] Shareholder Meeting Authority - The shareholder meeting is the company's authority body, responsible for electing and replacing directors, approving reports, and making decisions on profit distribution, capital changes, and other significant matters [1][3] - The company must ensure that shareholders can exercise their rights within the scope defined by the Company Law and the Articles of Association [1][3] Types of Shareholder Meetings - There are annual and temporary shareholder meetings, with annual meetings held within six months after the end of the previous fiscal year [4][5] - Temporary meetings must be convened within two months under specific circumstances, such as insufficient directors or significant losses [5][6] Proposal and Notification - Shareholders holding 1% or more of shares can propose agenda items for the shareholder meeting, and proposals must be submitted in writing [10][11] - Notifications for meetings must be made at least 20 days in advance for annual meetings and 15 days for temporary meetings [18][19] Voting and Decision-Making - Voting can be conducted in person or through authorized representatives, and the company must ensure a fair voting process [12][13] - The results of the voting must be announced immediately after the meeting, and detailed records must be kept for future reference [42][43] Legal Compliance - The rules must comply with national laws and regulations, and any violations can lead to invalidation of shareholder meeting resolutions [20][21] - The company is responsible for executing resolutions passed in shareholder meetings and must disclose relevant information as required by law [20][21]

General Principles - The rules aim to standardize the decision-making process and enhance the operational efficiency of the board of directors of Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd. [1] - The board consists of 9 directors, including 3 independent directors, and is led by a chairman elected by a majority of the board [1][2]. Board Authority and Responsibilities - The board is responsible for convening shareholder meetings, reporting to shareholders, executing resolutions, and making key decisions regarding the company's operations and investments [2][3]. - The chairman has specific powers, including presiding over meetings, signing important documents, and making emergency decisions in extraordinary circumstances [3]. Meeting Procedures - Board meetings are categorized into regular and temporary meetings, with at least one regular meeting held in each half of the year [4][5]. - A temporary meeting must be convened under certain conditions, such as a request from shareholders holding over 10% of voting rights or a proposal from one-third of the directors [4][5]. Voting and Decision-Making - Decisions require a majority of the board members to be present, and proposals must be clearly stated in the meeting notice [10][12]. - Voting is conducted by a show of hands or written ballot, with options for approval, disapproval, or abstention [20][22]. Documentation and Record-Keeping - Meeting records must include details such as the date, attendees, agenda, and voting results, and should be signed by the directors [30][31]. - The board secretary is responsible for managing meeting archives, which must be kept for at least 10 years [36][41].

天目药业公告，2025年上半年营业收入1.04亿元，同比增长73.97%。净利润1024.78万元，上年同期亏 损1850.07万元。 ...

格隆汇8月27日丨以岭药业（维权）(002603.SZ)公布2025年半年度报告，上半年公司实现营业收入40.40 亿元，同比下降12.26%；归属于上市公司股东的净利润6.69亿元，同比增长26.03%；归属于上市公司股 东的扣除非经常性损益的净利润6.41亿元，同比增长27.08%；基本每股收益0.4002元；拟向全体股东每 10股派发现金红利3.00元(含税)。 ...

Group 1 - The company announced that its operating revenue for the first half of 2025 was 3.358 billion yuan, representing a year-on-year decrease of 2.61% [1] - The net profit for the same period was 354 million yuan, showing a year-on-year decline of 7.48% [1]

Group 1 - The company reported a revenue of 713 million yuan for the first half of 2025, representing a year-on-year decline of 57.04% [1] - The net profit for the company was a loss of 78.29 million yuan, compared to a net profit of 393 million yuan in the same period last year [1]

Market Overview - The Chinese traditional medicine sector experienced a decline of 2.29% on August 27, with Zhen Dong Pharmaceutical leading the drop [1][2] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Stock Performance - Notable gainers included Wanbangde, which rose by 9.99% to a closing price of 9.58, and Qidi Pharmaceutical, which increased by 3.47% to 12.81 [1] - Major decliners included Zhen Dong Pharmaceutical, which fell by 6.77% to 8.81, and Jiu Zhi Tang, which decreased by 6.20% to 11.49 [2] Trading Volume and Capital Flow - The trading volume for Wanbangde was 724,000 shares, with a transaction value of 688 million yuan [1] - The traditional medicine sector saw a net outflow of 1.475 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.193 billion yuan [2][3] Individual Stock Capital Flow - Wanbangde had a net inflow of 81.79 million yuan from institutional investors, while it faced a net outflow of 26.07 million yuan from retail investors [3] - Qidi Pharmaceutical experienced a net inflow of 52.19 million yuan from institutional investors, with a net outflow of 32.13 million yuan from retail investors [3]

红日药业公告，2025年上半年营业收入27.95亿元，同比下降6.72%。净利润7863万元，同比下降 46.95%。公司计划不派发现金红利，不送红股，不以公积金转增股本。 ...

其他情况 根据公司公告，2025年上半年，公司毛利率为60.8%，同比-7.2个百分点；公司销售费用率为13.5%，同比-5.9个百分点，主要由于零售终端的相关费用以及营销推广活动减少；管理费用率为 责任编辑：史丽君 根据公司公告，2025年上半年，公司应付账款周转天数同比下降37天至35天；公司积极宣传同仁堂中医药产品和文化，积极投身各项中医药文化推广活动中去。该行认为，公司有望通过深化研 中金发布研报称，考虑同仁堂国药（03613）下半年费用投入，维持跑赢行业评级，考虑到公司积极拓展线上与线下销售渠道，持续丰富销售网络布局，该行维持目标价10.50港币，对应2025 中金主要观点如下： 香港市场恢复良好增长态势，积极拓展销售渠道 根据公司公告，1H25，公司中国香港市场收入为4.3亿港币，同比+30.3%，主要由于香港门店增加产品群销售，公司积极进行香港线下门店改造，全方位换新零售终端风貌。1H25，公司中国内 2025年上半年，销售费用率同步下降 ...